NCT01007292 2015-10-19
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
Astellas Pharma Inc
Phase 2 Completed
Clinical Trials
9 trialsNCT01100931 2015-10-19
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00818480 2015-09-04
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Astellas Pharma Inc
Phase 2 Completed
NCT01009775 2015-09-04
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Astellas Pharma Inc
Phase 2 Completed
NCT00514267 2015-08-13
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
Astellas Pharma Inc
Phase 1/2 Completed
NCT01038804 2013-09-18
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT00257478 2012-06-07
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
Astellas Pharma Inc
Phase 2 Completed
NCT00281541 2012-06-07
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
Astellas Pharma Inc
Phase 2 Completed
NCT01023386 2010-04-13
A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer
Astellas Pharma Inc
Phase 1 Completed